How investors read DSO financials

An investor may acquire support-company equity, an interest in another lawful entity, assets, debt, or a combination, depending on state ownership rules and the transaction. Financial reporting is a separate question: US GAAP consolidation follows the applicable voting-interest and variable-interest analysis, not the DSO label or the purchase perimeter. Diligence should preserve each legal entity’s books and show exactly how any combined view was produced.

​

Three views, three purposes

Produce all three from month one. The cost is low when you have two entities and prohibitive when you have twelve and no history.

​

Do not assume the practices consolidate

The threshold question is whether GAAP requires consolidation, permits no consolidation, or calls for another presentation. A management-services relationship alone does not answer it. Because US GAAP consolidation does not run on equity ownership alone. Under ASC 810, an entity consolidates a variable interest entity (VIE) when it is the primary beneficiary, meaning it has both power (the ability to direct the activities that most significantly affect the VIE’s economic performance) and economics (the obligation to absorb losses or the right to receive benefits that could be significant).¹ Facts that an ASC 810 analysis may examine include:

• Which activities most significantly affect the practice’s economic performance and who has current power to direct them
• The management fee, loss support, guarantees, loans, variable interests, and rights to significant benefits
• Kick-out, participating, termination, and substantive professional-control rights
• Related-party and de facto agent facts, including the substance and effect of transfer restrictions¹

The conclusion requires an auditor’s fact-specific analysis and may change when agreements or operations change. Do not draft clinical or ownership control to reach an accounting outcome. A reporting perimeter is not a transaction perimeter. If a consolidated or combined presentation includes patient-service revenue, identify which entities earned it, the GAAP basis or management convention for inclusion, eliminations, and the security or assets actually being offered. Show legal-entity and combined views with unambiguous labels.

​

Define the valuation unit before quoting EBITDA

Transaction materials may quote support-company EBITDA, practice EBITDA, adjusted consolidated EBITDA, or a pro forma cohort measure. Define the entity perimeter, period, eliminations, provider-compensation normalization, fee assumptions, and every adjustment before applying a multiple. Adviser-published practice, group, and platform ranges are directional market observations, not evidence that the same earnings automatically receive a higher value after aggregation. See DSO economics. Everything in diligence works toward a narrower question: which earnings belong to the transaction perimeter, are supportable and repeatable, and survive the legal, payer, provider, and capital structure being underwritten?

​

Quality-of-earnings adjustments

A quality-of-earnings (QoE) review normalizes reported EBITDA. The adjustments that recur in DSO deals:

​

The KPI set underwriters pull

Beyond the financials, diligence pulls operating metrics, because they predict whether the earnings persist. In dentistry the list is specific: Two metrics deserve extra attention. For the fee coverage ratio, show by PC whether collections cover clinical compensation, direct expenses, and the management fee. For same-store growth, use the group’s own cohort analysis. Major DSOs do not publish comparable same-store figures, so an unsupported industry benchmark adds little credibility.⁵

​

Red flags that kill or reprice deals

In rough order of severity: 1. An MSA or operating reality that conflicts with governing dental law. A prohibited fee or control term can threaten enforceability, licensure, collections, and the transaction thesis. The OCA and Packard decisions refused enforcement and a specific restitution theory under the law and claims before those courts; they do not make every payment universally unrecoverable.⁶ Quantify the state, entity, agreement, remedy, and operational exposure rather than predicting one buyer response. 2. Fees repriced retroactively before the raise. Restating prior periods at a higher fee to inflate DSO EBITDA is the classic tell. It converts a valuation question into a credibility question, and credibility is priced across the whole deal. 3. Negative PC equity propped up by undocumented intercompany loans. Shows the PC’s economics don’t work and that the group papers over it with transfers. Both problems, plus a documentation failure. See Intercompany loan note. 4. Commingled accounts. Shared accounts, expenses paid from the wrong entity, no separation. Signals that corporate separateness is nominal, the exact CPOD argument. 5. Management fees accrued but never paid in cash. Discussed above. 6. Friendly dentist concentration or instability. One nominee owning every PC, or an owner in dispute with the group, is a single point of failure over the entity holding all the payer contracts. 7. Clinical compensation that rewards unsupported treatment, referrals, or lay-directed sales. Production-based dentist compensation is not categorically unlawful. State control rules, documentation, payer terms, fee splitting, federal-program business, and the design of each metric matter. The California Aspen settlement specifically restricted per-sale hygienist incentives for the settling parties.⁷ 8. Stale agreements. An MSA drafted in 2021 and never reviewed, in a state that changed its law in 2025 or 2026. 9. Missing corporate records. No board minutes, no consents, no evidence the PC ever governed itself independently. 10. Payer participation with no documented transition path. A buyer will test every material payer by contract holder, TIN, NPI, location, rendering-provider linkage, assignment or consent rule, change-of-ownership requirement, and effective date. No universal rule says that every asset purchase terminates participation. The problem is closing without the payer’s written determination and an executable billing plan. See Working capital and AR lending.

​

What to build now

If a raise or sale is plausible within three years, the cheapest possible time to build these is today:

• Per-entity and DSO-standalone financials, monthly, from the start
• Every management fee calculated, invoiced, recorded, reconciled, and collected or aged under a documented policy
• Intercompany funding documented in the permitted form, with tax, entity, solvency, professional-practice, and pricing terms supported for the facts
• Intercompany balances reconciled monthly and equal-and-opposite
• A documented MSA review cadence plus event-driven reviews for legal, ownership, service, fee, and operating changes
• A valuation or pricing-support cadence matched to the formula, law, contract, and transaction risk
• Board minutes showing the PC governing itself
• A clean KPI pack with the metrics above tracked over time, including hygiene reappointment and write-offs by plan
• Identical charts of accounts across PCs, so consolidation is mechanical

Groups that do these things get through diligence in weeks. Groups that don’t spend months reconstructing, and pay for the gap in price.

​

Sources

1. FASB ASC 810, Consolidation. On the power-and-economics primary beneficiary test and the related-party/de facto agent guidance (including parties subject to agreements restricting transfer of their interests), see BDO, Control and Consolidation Under ASC 810 (May 2024); Deloitte, Primary Beneficiary. Confirm application to your facts with your auditors.
2. Hygiene production share and recall benchmarks: Dental Economics / Levin Group annual practice surveys, cited in DSO economics; recall as a valuation driver: BCAT, Dental hygiene recall.
3. Buyer diligence convention per transition-advisor checklists, e.g. ADS Transitions, due diligence checklist.
4. PPO write-off ranges as compiled from ADA fee-survey commentary and consultant datasets: Veritas Dental Resources, write-off reality check and PPO write-offs (consultant-sourced ranges).
5. Major DSOs report unit counts, not same-store sales; e.g. Heartland Dental’s public releases give practice counts and growth mix only (company release, August 5, 2025). No public same-store benchmark exists for the sector.
6. In re OCA, Inc., 552 F.3d 413 (5th Cir. 2008); Packard v. OCA, Inc., 624 F.3d 726 (5th Cir. 2010). See DSO case law. Colorado SB 25-194 (Dental Practice Act sunset revision, effective January 1, 2027): DDS Lawyers summary; see DSO laws by state.
7. California AG, settlement with Aspen Dental over corporate practice (May 7, 2026).